Novo Nordisk's shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe's largest by market capitalization. Novo Nordisk's ADR (NVO) (DK:NOVO.B), at ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Coca-Cola remains resilient amid GLP-1 health trends and geopolitical risks, with proactive innovation and a diversified ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

Prescription drug market expands rapidly due to AI in pharma, rising diseases, and global access to advanced therapies. The prescription drugs market will grow from $1,240.33B in 2024 to $2,151.63B by ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity market it carved out. The company has lost market share amid ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the company is trying to get back on track.

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic ... healthcare infrastructure investments and increasing awareness ...